Live Quote · NASDAQBEAMHealthcare· Biotechnology

Beam Therapeutics Inc.

$34.79 3.91%(+$1.31)
TickerSpark Score
71/100
Solid
53
Valuation
20
Profitability
100
Growth
84
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BEAM research report →

52-Week Range90% of range
Low
$15.60
Current
$34.79
High
$36.88
Company Overviewwww.beamtx.com

About the company

Beam Therapeutics Inc. , founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States.

CEO
John Evans
IPO
2020
Employees
393
HQ
Cambridge, MA, US

Price Chart

+75.00% · this period
$35.53$25.77$16.01Jul 02Dec 31Jul 02
Valuation
Market Cap
$3.58B
P/E
-54.36
P/S
21.82
P/B
3.09
EV/EBITDA
-110.58
Div Yield
0.00%
Profitability
Gross Margin
-32.43%
Op Margin
-226.58%
Net Margin
-39.66%
ROE
-5.89%
ROIC
-26.15%
Growth & Income
Revenue
$139.74M · 120.01%
Net Income
$-79,992,000 · 78.77%
EPS
$-0.81 · 82.31%
Op Income
$-383,693,000
FCF YoY
-1.08%
Performance & Tape
52W High
$36.88
52W Low
$15.60
50D MA
$30.97
200D MA
$27.63
Beta
2.20
Avg Volume
2.19M

Get TickerSpark's AI analysis on BEAM

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 30, 26Simon Amysell373
Jun 30, 26Evans John M.other25,000
Jun 29, 26Evans John M.other18,663
Jun 29, 26Evans John M.sell13,421
Jun 30, 26Evans John M.sell23,100
Jun 29, 26Evans John M.sell11,579
Jun 30, 26Evans John M.sell1,900
Jun 29, 26Evans John M.other6,337
Jun 30, 26Evans John M.other25,000
Jun 29, 26Evans John M.other18,663
Coverage · BEAM

Our BEAM coverage

Recent articles, reports, and earnings notes.

View all →
For Active Investors

Want a deeper read on BEAM?

Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.

Generate BEAM report →
Internal Compare

Similar companies

Peers in the same neighborhood.